| Literature DB >> 33060565 |
Roberto Raschetti1, Alexandre J Vivanti2, Christelle Vauloup-Fellous3, Barbara Loi1, Alexandra Benachi2, Daniele De Luca4,5.
Abstract
A number of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have been reported in neonates. Here, we aim to clarify the transmission route, clinical features and outcomes of these infections. We present a meta-analysis of 176 published cases of neonatal SARS-CoV-2 infections that were defined by at least one positive nasopharyngeal swab and/or the presence of specific IgM. We report that 70% and 30% of infections are due to environmental and vertical transmission, respectively. Our analysis shows that 55% of infected neonates developed COVID-19; the most common symptoms were fever (44%), gastrointestinal (36%), respiratory (52%) and neurological manifestations (18%), and lung imaging was abnormal in 64% of cases. A lack of mother-neonate separation from birth is associated with late SARS-CoV-2 infection (OR 4.94 (95% CI: 1.98-13.08), p = 0.0002; adjusted OR 6.6 (95% CI: 2.6-16), p < 0.0001), while breastfeeding is not (OR 0.35 (95% CI: 0.09-1.18), p = 0.10; adjusted OR 2.2 (95% CI: 0.7-6.5), p = 0.148). Our findings add to the literature on neonatal SARS-CoV-2 infections.Entities:
Mesh:
Year: 2020 PMID: 33060565 PMCID: PMC7566441 DOI: 10.1038/s41467-020-18982-9
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Study flow chart.
Flow chart prepared according to the PRISMA guidelines template for meta-analyses.
Characteristics of articles included in the systematic review.
| First author/reference No. | Article type | Country | Publication stage | Quality score | Overall quality | No. neonates |
|---|---|---|---|---|---|---|
| Abasse[ | Case report | Francea | PR | 6 | Good | 1 |
| Aghdam[ | Case report | Iran | PR | 4 | Intermediate | 1 |
| Alonso Diaz[ | Case report | Spain | PR | 5 | Intermediate | 1 |
| Alzamora[ | Case report | Peru | PR | 3 | Intermediate | 1 |
| Ayed[ | Case series | Kuwait | Preprint | 1 | Low | 2 |
| Banerjee[ | Case series | India | PR | 2 | Low | 6 |
| Barbero[ | Retrospective cohort study | Spain | PR | n.a. | Intermediate | 1 |
| Buonsenso[ | Case series | Italy | PR | 4 | Intermediate | 1 |
| Carosso[ | Case report | Italy | PR | 4 | Intermediate | 1 |
| Chacon-Aguilar[ | Case report | Spain | PR | 5 | Intermediate | 1 |
| Coronado Munoz[ | Case report | USA | PR | 4 | Intermediate | 1 |
| Demirjian[ | Case report | UK | PR | 4 | Intermediate | 1 |
| Dong[ | Case report | China | PR | 6 | Good | 1 |
| Dumpa[ | Case report | USA | PR | 6 | Good | 1 |
| Eghbalian[ | Case report | Iran | PR | 4 | Intermediate | 2 |
| Feng[ | Case series | China | PR | 3 | Intermediate | 4 |
| Fenizia[ | Case series | Italy | PP | 5 | Intermediate | 2 |
| Ferrazzi[ | Case series | Italy | PR | 1 | Low | 3 |
| Garazzino[ | Case series | Italy | PR | 2 | Low | 15 |
| Gonzales Brabin[ | Case report | Spain | PR | 3 | Intermediate | 1 |
| Gordon[ | Case report | UK | PR | 2 | Low | 1 |
| Gregorio-Hernandez[ | Case series | Spain | PR | 5 | Intermediate | 3 |
| Groß[ | Case series | Germany | PR | 5 | Intermediate | 1 |
| Han[ | Case report | South Korea | PR | 6 | Good | 1 |
| Hantoushzadeh[ | Case series | Iran | PR | 6 | Good | 1 |
| Hasan[ | Case series | Bangladesh | Preprint | 6 | Good | 7 |
| Hu[ | Case series | China | PR | 6 | Good | 1 |
| Ibarra Rios[ | Case report | Mexico | Preprint | 5 | Intermediate | 1 |
| Kanburoglu[ | Case report | Turkey | PR | 1 | Low | 1 |
| Kayem[ | Case series | France | PR | 1 | Low | 1 |
| Kirtsman[ | Case report | Canada | PR | 6 | Good | 1 |
| Knight[ | Retrospective cohort study | UK | PR | n.a. | n.a. | 12 |
| Kulkarni[ | Case report | India | PR | 6 | Good | 1 |
| L’Huillier[ | Case series | Switzerland | PR | 1 | Low | 1 |
| Lorenz[ | Case report | Germany | PR | 6 | Good | 1 |
| Martinez-Peres[ | Case series | Spain | PR | 1 | Low | 4 |
| Marzollo[ | Case report | Italy | PR | 6 | Good | 1 |
| Meredith[ | Case series | UK | PR | 1 | Low | 1 |
| Meslin[ | Case series | France | PR | 6 | Good | 4 |
| Mithal[ | Case series | USA | PR | 3 | Intermediate | 4 |
| Needleman[ | Case report | USA | PR | 4 | Intermediate | 1 |
| Ng[ | Case series | UK | PR | 6 | Good | 1 |
| Oncel[ | Case series | Turkey | PR | 6 | Good | 4 |
| Paret[ | Case series | USA | PR | 3 | Intermediate | 1 |
| Patanè[ | Case series | Italy | PR | 6 | Good | 2 |
| Patil[ | Case series | USA | PR | 4 | Intermediate | 3 |
| Pierce-Williams[ | Case series | USA | PR | 5 | Intermediate | 1 |
| Piersigilli[ | Case report | Belgium | PR | 6 | Good | 1 |
| Precit[ | Case report | USA | PR | 5 | Intermediate | 1 |
| Salik[ | Case report | USA | PR | 1 | Low | 1 |
| Salvatori[ | Case series | Italy | PR | 6 | Good | 2 |
| Savasi[ | Case series | Italy | PR | 1 | Low | 4 |
| Schwartz[ | Case series | Iran | PR | 5 | Intermediate | 19 |
| Siddhi[ | Case report | UK | PR | 3 | Intermediate | 1 |
| Sinelli[ | Case report | Italy | PR | 6 | Good | 1 |
| Sisman[ | Case report | USA | PR | 6 | Good | 1 |
| Sola[ | Case series | Latin Americab | PR | 5 | Intermediate | 6 |
| Sun D[ | Case report | China | PR | 6 | Good | 1 |
| Sun[ | Case series | China | PR | 6 | Good | 1 |
| Verma[ | Case series | USA | PR | 2 | Low | 1 |
| Vivanti[ | Case report | France | PR | 6 | Good | 1 |
| Wang[ | Case report | China | PR | 6 | Good | 1 |
| Wang X[ | Case report | China | PR | 6 | Good | 1 |
| Wardell[ | Case series | USA | PR | 6 | Good | 4 |
| White[ | Case series | USA | PR | 6 | Good | 3 |
| Wu[ | Case series | China | PR | 5 | Intermediate | 3 |
| Xia[ | Case series | China | PR | 4 | Intermediate | 3 |
| Xiao[ | Cross-sectional study | China | PR | n.a. | Intermediate | 2 |
| Yu[ | Case report | China | PR | 4 | Intermediate | 1 |
| Zamaniyan[ | Case report | Iran | PR | 6 | Good | 1 |
| Zeng H[ | Case series | China | PR | 2 | Low | 2 |
| Zeng L[ | Case series | China | PR | 6 | Good | 3 |
| Zeng LK[ | Case report | China | PR | 6 | Good | 1 |
| Zhang[ | Case series | China | PR | 5 | Intermediate | 2 |
| Total | 176 | |||||
For articles reporting both infected and non-infected neonates, only those with proven infection (defined as at least one positive nasopharyngeal swab, and/or the presence of specific IgM) were included in the review. The methodological quality of case reports and case series was evaluated using the Mayo Evidence-Based Practice Center tool[103], specifically dedicated to the quality evaluation of this type of articles and summarized both as a 0–8 score and as overall qualitative evaluation. The tool was not applied to the retrospective cohort or cross-sectional studies included in the review.
n.a. not applicable, PR peer-reviewed.
aThis case was observed in Mayotte Island, an overseas French department in in the Indian Ocean.
bThis study was conducted in seven neonatal units affiliated to the network of the Latin American Neonatal Society (Sociedad Iberoamericana de Neonatologia (SIBENA); in detail, positive SARS-CoV-2 neonates included in this review were from Peru (n = 3), Dominican Republic (n = 2) and Honduras (n = 1).
Basic data of the reported neonates.
| Neonates (176) | Summary statistics | Min–max range |
|---|---|---|
| Gestational age (weeks) | 36.9 (3.4) | 26–41 |
| Birth weight (grams) | 2782 (799) | 900–4500 |
| Birth weight | 0 [−0.8;0.8] | −2.41–2.41 |
| Male sex | 63 (62.4%)a | – |
| Caesarean section | 66 (37.5%) | – |
| 5′ Apgar score | 9 [8.5;10] | 2–10 |
| Postnatal age at the diagnosis (days) | 5 [2;15] | 0–30 |
| Symptomatic neonates | 97 (55.1%) | – |
Data are expressed as mean (standard deviation) or median [interquartile range], min–max or number (%), as appropriate.
aMale sex percentage is referred to 101 neonates, as gender data were missing for the others, despite repeated requests to the authors of the articles.
Fig. 2Classification of neonatal SARS-CoV-2 infections according to the definition of maternal, fetal, and neonatal SARS-CoV-2 infections.
Classification is based on a system including several virological tests (on placental tissues, amniotic fluid, cord and newborn blood or nasopharyngeal swabs), as well as the presence of clinical manifestations[16]. Cases are divided into: (1) congenital infections, (2) intrapartum acquired infections, or (3) postpartum acquired infections and into five mutually exclusive categories of the likelihood of infection: “confirmed”, “probable”, “possible”, “unlikely”, and “not infected”. Classification was applied to 122 cases (for 54 neonates, data needed to classify the infection were missing despite repeated requests to the authors of the articles). Areas in blue depict the infections confirmed or supposed to be environmentally acquired (i.e.: postpartum), while areas in brown depict confirmed or supposed to be vertically (either intrapartum or congenitally) transmitted infections; numbers represent the %.
Distribution of clinical features in the subgroup of neonates presenting with signs or symptoms compatible with COVID-19.
| Clinical features | Neonates (%) |
|---|---|
| Respiratory | 51 (52.5%) |
| Fever | 43 (44.3%) |
| Gastrointestinal | 35 (36%) |
| Neurological | 18 (18.6%) |
| Hemodynamic | 10 (10.3%) |
| Others | 9 (9.2%) |
Clinical features are listed in order of frequency; multiple features are possible in a patient; percentage is calculated for the group of symptomatic neonates (n = 97). More details in the text.
Fig. 3Effect of mother-neonate separation and breastfeeding on the occurrence of late SARS-CoV-2 infections.
Late infections are defined as those diagnosed after the first 72 h of life. Diamonds and horizontal lines represent the odds ratio (OR) and its 95% confidence interval (CI), respectively. Horizontal axis is on a log scale for better visualization; vertical hatched line represents OR = 1. Analysis was performed for 133 neonates for whom infection could have been classified as early- or late-onset. Figure illustrates OR 4.94 (95% CI: 1.98–13.08), p = 0.0002, for lack of mother-neonate separation from birth and OR 0.35 (95% CI: 0.09–1.18), p = 0.10 for breastfeeding. Analyses were performed with two-sided Fisher exact test.